2022 American Transplant Congress

TOPIC: Clinical Science » Lung » 64 - Lung: All Topics

The SHELTER Trial of Transplanting Donor Hepatitis C Virus RNA+ Lungs Into Uninfected Recipients
V. Potluri¹, P. Reese¹, S. Prenner¹, H. Mentch¹, D. Goldberg², T. Claridge¹, J. Smith¹, C. Gentile¹, V. Van Deerlin¹, R. Reddy¹, T. Fallah¹, C. Bermudez¹, M. Crespo¹, J. Diamond¹
The Unique Course of dd-cfDNA After Lung Transplant
D. Levine¹, C. Giner¹, C. Pham², R. Woodward³, A. Roux⁴
Therapeutic Drug Monitoring of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Patients
S. Sial, K. Cunningham, J. Moore, C. Dagostino, K. Lang, C. Kane
Top Molecules Associated with CLAD in Lung Transplants Are Shared Between Mucosal Biopsies, Transbronchial Biopsies, and Kidney Transplant Biopsies at Risk of Progression
M. Mackova¹, K. Halloran², P. F. Halloran¹, .. and the INTERLUNG Study Group³
Transbronchial Cryobiopsy vs Conventional Forceps Biopsy in Lung Transplant Recipients Multicenter Study
M. Svorcova¹, J. Vachtenheim¹, J. Havlin¹, P. Jakubec², D. Rakita³, J. Balko⁴, J. Simonek¹, J. Kolarik¹, J. Pozniak¹, R. Lischke¹
Utility of Bronchoalveolar Lavage Cytology for Detection of Malignancy or Infection in Lung Transplant Recipients
G. Cerro Chiang¹, R. Rampolla²
Utility of Cytomegalovirus T-Cell Immunity Panel to Predict CMV Infections in Lung Transplant Recipients
R. W. Lincoln¹, B. J. Pierce¹, C. Pham¹, S. W. Yau², A. Goodarzi², J. G. Youssef², H. J. Huang²
Variability In Plasma Donor-derived Cell-free DNA Levels With CLAD More Than 5-years After Lung Transplantation: Pilot Data
D. Levine¹, D. Ross²